16 September 2026 editorial review · Item
Sernova Cell Pouch Bio-hybrid Organ: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: The September 2024 sponsor source explicitly says all six insulin-independent Cohort A recipients received combined pouch and intraportal transplantation. Added that qualifier directly beside summary, criterion and 6/6 body claims. Interim 8/12 and long-lived tissue remain sponsor reports; neither establishes the pouch-alone effect. Chronic immunosuppression and funding-dependent Cohort C remain limits.
- Registry NCT03513939: ACTIVE_NOT_RECRUITING; updated 2026-02-25; enrollment 17 (ESTIMATED); primary completion 2026-10 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: TP.0000000000000864; ajt.14547.